Want to see GB:TCF full AI Analyst Report?
Top Page
Evgen Pharma
(LSE:TCF)
Select Model
Select Model
Rating:42Neutral
Price Target:
0.16 p
▼(-14.21% Downside)
Action:Reiterated
Date:09/29/26
The score is primarily held back by weak financial performance—continued losses, irregular revenue, and persistent cash burn alongside shrinking equity—suggesting ongoing financing/dilution risk. Technical signals reinforce the risk, with a clear downtrend and very weak momentum. Valuation is difficult to support with a negative P/E and no dividend yield information.
Positive Factors
Proprietary drug-discovery platform
Ownership of the Sulforadex platform gives Evgen a defined technology base from which to develop multiple therapeutics. Its application across oncology and inflammatory or disease areas may support a broader development strategy and create future partnering opportunities.
Negative Factors
Persistent operating losses
Persistent operating and net losses show that the company has not yet converted its development activities into sustainable profitability. The larger reported loss in 2026 increases uncertainty around the path to breakeven and may constrain internal funding for pipeline advancement.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary drug-discovery platform
Ownership of the Sulforadex platform gives Evgen a defined technology base from which to develop multiple therapeutics. Its application across oncology and inflammatory or disease areas may support a broader development strategy and create future partnering opportunities.
Read all positive factors
Evgen Pharma (TCF) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£4.92M
Dividend YieldN/A
Average Volume (3M)1.79M
Price to Earnings (P/E)―
Beta (1Y)0.85
Revenue GrowthN/A
EPS Growth55.56%
CountryUK
Employees9
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding2,732,297,000
10 Day Avg. Volume2,889,457
30 Day Avg. Volume1,786,266
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.54
Price to Sales (P/S)0.00
P/FCF Ratio-1.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)N/A
Evgen Pharma Business Overview & Revenue Model
Company Description
Theracryf Plc operates as a clinical-stage biotechnology firm, dedicated to advancing treatments for oncological diseases and various brain disorders affecting behavior. Its primary therapeutic asset, SFX-01, is currently progressing through Phase...
How the Company Makes Money
Evgen Pharma is a clinical-stage biopharmaceutical company and, based on publicly available information, it does not appear to generate recurring product revenue from marketed drugs. Its typical monetization model is expected to be (i) partnering/...
Evgen Pharma Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
55
Neutral
Cash Flow
24
Negative
| Breakdown | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 396.00K | 442.00K | 0.00 |
| Gross Profit | -16.00K | -2.11M | 385.00K | 429.00K | -16.00K |
| EBITDA | -3.67M | -2.06M | -3.55M | -4.99M | -3.15M |
| Net Income | -3.53M | -1.94M | -3.14M | -4.04M | -2.73M |
Balance Sheet | |||||
| Total Assets | 4.81M | 7.63M | 3.06M | 6.17M | 9.64M |
| Cash, Cash Equivalents and Short-Term Investments | 1.54M | 4.11M | 2.00M | 5.00M | 9.03M |
| Total Debt | 11.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 2.10M | 1.66M | 721.00K | 833.00K | 411.00K |
| Stockholders Equity | 2.72M | 5.97M | 2.34M | 5.34M | 9.23M |
Cash Flow | |||||
| Free Cash Flow | -2.56M | -2.37M | -3.00M | -4.03M | -2.56M |
| Operating Cash Flow | -2.55M | -2.37M | -3.00M | -4.03M | -2.56M |
| Investing Cash Flow | 916.00K | -2.08M | 0.00 | 4.52M | 1.48M |
| Financing Cash Flow | -7.00K | 4.55M | 0.00 | 0.00 | 0.00 |
Evgen Pharma Technical Analysis
Neutral
0.19
Price Trends
0.19
Negative
0.21
Negative
0.21
Negative
Market Momentum
>-0.01
Negative
44.78
Neutral
66.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:TCF, the sentiment is Neutral. The current price of 0.19 is above the 20-day moving average (MA) of 0.18, above the 50-day MA of 0.19, and below the 200-day MA of 0.21, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 44.78 is Neutral, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GB:TCF.
Evgen Pharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | £115.16M | -17.92 | 90.29% | ― | ― | 69.01% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | £41.92M | -8.24 | -284.01% | ― | ― | -105.65% | |
47 Neutral | £44.83M | -3.59 | -409.57% | ― | ― | 18.57% | |
44 Neutral | £20.59M | -2.64 | -559.87% | 17.86% | ― | 5.62% | |
42 Neutral | £4.92M | -1.80 | -93.92% | ― | ― | 55.56% | |
39 Underperform | £1.78M | -0.71 | -71.49% | ― | -34.36% | 57.45% |
* Healthcare Sector Average
GB:TCF
Evgen Pharma
0.18
-0.04
-18.18%
GB:IMM
ImmuPharma
3.30
-7.80
-70.27%
GB:SAR
Sareum Holdings
30.00
6.50
27.66%
GB:SCLP
Scancell Holdings
9.50
-0.25
-2.56%
GB:HEMO
HemoGenyx Pharmaceuticals Plc
650.00
-515.00
-44.21%
GB:VAL
ValiRx plc
0.14
-0.39
-74.29%
Evgen Pharma Corporate Events
Business Operations and StrategyFinancial DisclosuresPrivate Placements and FinancingProduct-Related Announcements
TheraCryf advances lead addiction drug to clinic-ready stage as losses widen
Positive
Sep 28, 2026
TheraCryf reported final results for the year to 31 March 2026, highlighting strong operational progress on its lead orexin-1 antagonist for addiction, which has advanced through late-stage preclinical development on time and budget. The company c...
Business Operations and StrategyFinancial Disclosures
TheraCryf Sets Results Date as Lead Addiction Therapy Nears Clinical Readiness
Positive
Sep 14, 2026
TheraCryf plc, the biotech group developing treatments for addiction and neuropsychiatric conditions, is advancing a de-risked, best-in-class orexin-1 receptor antagonist through final pre-clinical trials and operates a virtual, partnership-focuse...
Private Placements and FinancingShareholder MeetingsStock Split
TheraCryf Wins Shareholder Backing for £1.05m Fundraise and Share Subdivision
Positive
Sep 7, 2026
TheraCryf plc, the biotech company developing treatments for addiction and other neuropsychiatric disorders, has secured shareholder approval for a capital raising of about £1.05 million through a placing and subscription. Investors also back...
Business Operations and StrategyPrivate Placements and Financing
TheraCryf raises £1.05m to advance addiction drug towards Phase 1 trials
Positive
Aug 20, 2026
TheraCryf plc has announced a proposed £1.05 million equity raise via a placing and subscription of new shares, priced at 0.18 pence each and directed to existing and new investors, to strengthen its balance sheet. The capital injection is in...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.